Faron Pharmaceuticals Ltd.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”).

Faron’s second candidate Clevegen® is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients.

Faron operates in an agile way by sourcing its innovations primarily from academia. The inventors of the projects are close scientific collaborators with the Company and continue to be involved in further developments of the projects. As much of the development work up to the proof-of-concept stage can be contracted to the innovators’ labs, Faron is able to maintain a lean operating structure. As a result, Faron can run a relatively extensive drug development operation with significantly fewer members of staff and lower costs than would be possible for a typical drug development company.

Based in Turku, Finland, Faron Pharmaceuticals is listed in AIM under the ticker ‘FARN’.



henkilo_faron.jpg Markku Jalkanen